Pyxis Oncology, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Pyxis Oncology, Inc. (PYXS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Pyxis Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.53M, a 83.35% increase year-over-year.
- Pyxis Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.21M, a 66.68% decline year-over-year.
- Pyxis Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $2.08M, a 24.92% decline year-over-year.
- Pyxis Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.07M, a 3.09% increase year-over-year.
- Pyxis Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $11.80M, a 8.84% decline from fiscal 2024.
- Pyxis Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $12.95M, a 23.61% decline from fiscal 2023.
- Pyxis Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $16.95M, a 7.50% increase from fiscal 2022.
- Pyxis Oncology, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $15.76M, a 144.74% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.53M 10-Q · filed 2026-08-13 | $6.74M derived: sum of 2 quarters · filed 2026-08-13 | $8.82M derived: sum of 3 quarters · filed 2026-08-13 | $11.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.21M 10-Q · filed 2026-08-13 | $3.29M derived: sum of 2 quarters · filed 2026-08-13 | $6.37M derived: sum of 3 quarters · filed 2026-08-13 | $9.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $5.16M derived: sum of 2 quarters · filed 2026-03-23 | $8.17M derived: sum of 3 quarters · filed 2026-08-13 | $11.80M 10-K · filed 2026-03-23 |
| 2025-09-30 | $3.07M 10-Q · filed 2025-11-03 | $6.09M derived: sum of 2 quarters · filed 2026-08-13 | $9.72M 10-Q · filed 2025-11-03 | $12.49M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $3.02M 10-Q · filed 2026-08-13 | $6.65M derived: sum of 2 quarters · filed 2026-08-13 | $9.42M derived: sum of 3 quarters · filed 2026-08-13 | $12.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $3.63M 10-Q · filed 2026-08-13 | $6.40M derived: sum of 2 quarters · filed 2026-08-13 | $9.38M derived: sum of 3 quarters · filed 2026-08-13 | $12.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2024-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $5.75M derived: sum of 2 quarters · filed 2026-03-23 | $8.63M derived: sum of 3 quarters · filed 2026-03-23 | $12.95M 10-K · filed 2026-03-23 |
| 2024-09-30 | $2.98M 10-Q · filed 2025-11-03 | $5.85M derived: sum of 2 quarters · filed 2025-11-03 | $10.17M 10-Q · filed 2025-11-03 | $13.39M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $2.87M 10-Q · filed 2025-08-14 | $7.19M derived: sum of 2 quarters · filed 2025-08-14 | $10.41M derived: sum of 3 quarters · filed 2025-08-14 | $15.59M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $4.32M 10-Q · filed 2025-08-14 | $7.54M derived: sum of 2 quarters · filed 2025-08-14 | $12.71M derived: sum of 3 quarters · filed 2025-08-14 | $16.38M derived: sum of 4 quarters · filed 2025-08-14 |
| 2023-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $8.39M derived: sum of 2 quarters · filed 2025-03-18 | $12.06M derived: sum of 3 quarters · filed 2025-03-18 | $16.95M 10-K · filed 2025-03-18 |
| 2023-09-30 | $5.18M 10-Q · filed 2024-11-12 | $8.85M derived: sum of 2 quarters · filed 2024-11-12 | $13.73M 10-Q · filed 2024-11-12 | $17.63M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $3.67M 10-Q · filed 2024-08-14 | $8.55M derived: sum of 2 quarters · filed 2024-08-14 | $12.45M derived: sum of 3 quarters · filed 2024-08-14 | $16.90M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $4.88M 10-Q · filed 2024-08-14 | $8.78M derived: sum of 2 quarters · filed 2024-08-14 | $13.23M derived: sum of 3 quarters · filed 2024-08-14 | $17.24M derived: sum of 4 quarters · filed 2024-08-14 |
| 2022-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $8.35M derived: sum of 2 quarters · filed 2024-03-21 | $12.36M derived: sum of 3 quarters · filed 2024-03-21 | $15.76M 10-K · filed 2024-03-21 |
| 2022-09-30 | $4.45M 10-Q · filed 2023-11-07 | $8.46M derived: sum of 2 quarters · filed 2023-11-07 | $11.87M 10-Q · filed 2023-11-07 | $14.98M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $4.01M 10-Q · filed 2023-08-11 | $7.42M derived: sum of 2 quarters · filed 2023-08-11 | $10.53M derived: sum of 3 quarters · filed 2023-08-11 | $10.84M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $3.40M 10-Q · filed 2023-08-11 | $6.52M derived: sum of 2 quarters · filed 2023-08-11 | $6.82M derived: sum of 3 quarters · filed 2023-08-11 | $7.39M derived: sum of 4 quarters · filed 2023-08-11 |
| 2021-12-31 | $3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $3.42M derived: sum of 2 quarters · filed 2023-03-22 | $3.99M derived: sum of 3 quarters · filed 2023-03-22 | $6.44M 10-K · filed 2023-03-22 |
| 2021-09-30 | $307.00K 10-Q · filed 2022-11-01 | $879.00K derived: sum of 2 quarters · filed 2022-11-01 | $3.33M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $572.00K 10-Q · filed 2022-08-15 | $3.02M derived: sum of 2 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $2.45M 10-Q · filed 2022-08-15 | |||
| 2020-12-31 | $44.00K 10-K · filed 2022-03-29 | |||
| 2020-09-30 | $11.00K 10-Q · filed 2021-11-15 | $20.00K derived: sum of 2 quarters · filed 2021-11-15 | $29.00K derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $9.00K 10-Q · filed 2021-11-15 | $18.00K derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-03-31 | $9.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |